Pfizer to License RAGE Modulators from TransTech
September 27th 2006Pfizer (New York, NY, www.pharmtech.com) will license TransTech Pharma's (High Point, NC, www.ttpharma.com) portfolio of large- and small-molecule compounds that target the receptor for advanced glycation end products (RAGE), which have potential use in treating Alzheimer's disease.
Fastest Drug Developers Outperform Peers
September 27th 2006Drugs developed by the fastest companies each gained an average of $1.1 billion in incremental prescription revenue and saved an average of $30 million in out-of-pocket development costs, compared to those of the slowest companies, according to Tufts University's Center for the Study of Drug Development (CSDD).
Fresenius Kabi and Sandoz to Co-Develop HESylated Protein
August 31st 2006Fresenius Kabi (Bad Homburg, Germany, www.fresenius-kabi.com) and Sandoz, (Holzkirchen, Germany, www.sandoz.com), have entered into a partnership to develop a second-generation version of an un-named Sandoz recombinant protein using Fresenius Kabi's "HESylation" technology.
Gamma Radiation Proves Effective in Vaccine Development
August 31st 2006Vaccines made with bacteria killed by gamma rays may be more effective than those made using standard heat or chemical inactivation, according to Sandip Datta, MD, assistant professor in the department of medicine, University of California, San Diego (http://www.ucsd.edu).
QSV Biologics, Ltd. To Manufacture Synthetic Vitronectin for Tissue Therapies, Ltd.
August 31st 2006QSV Biologics, Ltd. (Edmonton, Canada, www.qsvbiologics.com) has signed a contract with Tissue Therapies Limited (Brisbane, Australia, www.tissuetherapies.com) for the cGMP manufacture of clinical quantities of synthetic Vitronectin (a component of the wound-healing treatment VitroGro) and a single-protein chimeric form of VitroGro.
Laureate to Produce Antibody for Lpath
August 31st 2006Lpath, Inc. (San Diego, CA, www.lpath.com) and Laureate Pharma, Inc. (Princeton, NJ, www.laureatepharma.com) have entered into an agreement for Laureate to manufacture Lpath's recombinant humanized monoclonal antibody, "Sphingomab," against bioactive lipids.
FDA Extends CRADA with EduNeering for Inspection Training
July 27th 2006EduNeering (Princeton, NJ, www.eduneering.com) and the Food and Drug Administration (Washington, DC, www.fda.gov) have extended their existing Cooperative Research and Developing Agreement (CRADA), originally formed in 1999, for five more years.
Indian Association Calls for Biotechnology Fund
July 27th 2006The Associated Chambers of Commerce and Industry of India (Assocham, www.assocham.org) have called for the establishment of a National Biotechnology Development Fund and a National Nanotechnology Development Fund, with outlays of approximately US $1 billion (Rs. 4,800 crore) and US $2 billion (Rs. 9,600 crore) respectively.
Emisphere and Roche To Develop Oral Formulations of Large Molecules
July 27th 2006Emisphere Technologies, Inc. (Tarrytown, NY, www.emisphere.com) has signed a multi-product research agreement with Roche (Basel, Switzerland, www.roche.com) to explore the use of Emisphere's eligen technology in feasibility studies for new oral formulations of Roche molecules.
The Pharmaceutical Institute Launches Online Biopharmaceutical Training Program
July 27th 2006Biotechnology and pharmaceutical companies seeking to train employees, or even to create their own "online university" can now partner with The Pharmaceutical Institute (PI, Raleigh, NC, www.pharmainstitute.com).